Clinical trials
Completed trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
5,911 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 11 |
| 2001 | 13 |
| 2002 | 30 |
| 2003 | 56 |
| 2004 | 105 |
| 2005 | 103 |
| 2006 | 181 |
| 2007 | 231 |
| 2008 | 261 |
| 2009 | 301 |
| 2010 | 316 |
| 2011 | 350 |
| 2012 | 379 |
| 2013 | 338 |
| 2014 | 365 |
| 2015 | 356 |
| 2016 | 369 |
| 2017 | 389 |
| 2018 | 303 |
| 2019 | 308 |
| 2020 | 281 |
| 2021 | 284 |
| 2022 | 182 |
| 2023 | 162 |
| 2024 | 98 |
| 2025 | 40 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5,911 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 306 |
| Novartis Pharmaceuticals | 278 |
| Pfizer | 251 |
| Eli Lilly and Company | 232 |
| Boehringer Ingelheim | 227 |
| GlaxoSmithKline | 224 |
| Bayer | 220 |
| Astellas Pharma Inc | 205 |
| Takeda | 197 |
| Novo Nordisk A/S | 187 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 325 |
| Neoplasms | 178 |
| Carcinoma, Non-Small-Cell Lung | 149 |
| Diabetes Mellitus | 144 |
| Breast Neoplasms | 123 |
| Arthritis, Rheumatoid | 116 |
| Asthma | 96 |
| Hypertension | 96 |
| Pulmonary Disease, Chronic Obstructive | 89 |
| Stomach Neoplasms | 89 |
Trials
Showing 26 to 50 of 5,911. Each trial links to its page on Pharma Observatory.
5,811 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.